AIM ImmunoTech is trading 7.53% down in pre-market at $0.26 after reporting second-quarter results on August 7, 2026, which showed a net loss of $3.79 million.
- Revenue edged up to $0.026 million, while net loss widened from $2.79 million a year earlier.
- Cash reached $9.9 million at June 30; DURIPANC enrollment was completed.
- Broader markets were only modestly lower, offering limited explanation; continued losses and cash burn likely outweighed the development milestone.